 |
|
|
| |
NGM282, a Novel Variant of FGF19, Significantly Reduces Hepatic Steatosis and Key Biomarkers of NASH: Results of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo Controlled Trial in Biopsy-Confirmed NASH Patients
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Stephen A.Harrison, Manal F.Abdelmalek, James F.Trotter,
Angelo H.Paredes, Hays L.Arnold, MarceloKugelmas, Mustafa R.Bashir, LeiLing, Stephen J.Rossi, Alex M.DePaoli, Mary E.Rinella, Rohit Loomba
|
| |
|
|
|
|
|
